Sign In
Buy SMMT
$15.07
+0.210 (+1.41%)
At Close: Jun 03, 2026
Summit Raises $200 Million; Also Expands License Territories for Ivonescimab
05:30am, Monday, 03'rd Jun 2024
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that the Company received and accepted an unsolicited offer fro
Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
08:00am, Saturday, 01'st Jun 2024
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) announced that the Journal of the American Medical Association (JAMA) published
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) announced that, on May 24, 2024, our partner, Akeso Inc. (Akeso, HKEX Code: 992
Biotech Stock Volatile After Upbeat Trial data
10:19am, Friday, 31'st May 2024
The shares of Summit Therapeutics Inc (NASDAQ:SMMT) appear to be headed for a minor correction after yesterday's skyrocket.
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:00pm, Thursday, 30'th May 2024
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:00pm, Thursday, 30'th May 2024
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of
Summit Therapeutics' stock surges as lung-cancer treatment vies with Merck's blockbuster
04:29pm, Thursday, 30'th May 2024
Shares of Summit Therapeutics Inc. SMMT, +272.06% jumped more than 270% Thursday after the company said its experimental cancer drug outperformed Merck & Co. Inc.'s blockbuster Keytruda in a late-stag
Summit Therapeutics cancer therapy succeeds in late-stage China study
03:39pm, Thursday, 30'th May 2024
Summit Therapeutics said on Thursday its experimental therapy to treat patients with a type of lung cancer met the main goal of a late-stage study conducted in China.
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that the Phase III clinical trial, HARMONi-2 or AK112-303, met
Why Summit Therapeutics Stock Is Sinking Today
12:13pm, Tuesday, 28'th May 2024
Summit Therapeutics' stock is falling sharply for the second consecutive trading day. The sell-off began after the company revealed disappointing late-state data for its lead pipeline candidate.
Summit: A Few Catalysts In Q2 Of 2024 To Carry The Tide
01:30pm, Wednesday, 08'th May 2024
NPMA decision on whether to approve Summit Therapeutics Inc.'s ivonescimab for the treatment of patients with EGFR-mutant metastatic non-squamous NSCLC following TKI progression is expected in Q2 of 2
Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer
11:02am, Monday, 06'th May 2024
Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer
Summit Therapeutics Inc. (SMMT) Q1 2024 Earnings Call Transcript
10:00pm, Wednesday, 01'st May 2024
Summit Therapeutics Inc. (NASDAQ:SMMT ) Q1 2024 Earnings Conference Call May 1, 2024 9:00 AM ET Company Participants Dave Gancarz - Chief Business and Strategy Officer Bob Duggan - Chairman of the Boa
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024
07:00am, Wednesday, 01'st May 2024
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for
Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024
04:30pm, Wednesday, 24'th Apr 2024
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its first quarter 2024 financial results
